Amyotrophic Lateral Sclerosis Market Research Report - Forecast to 2023

Overview:

Amyotrophic lateral sclerosis (ALS) belongs to a group of rare neurological disorders. This neurodegenerative disease badly impacts the nerve cells in the brain and the spinal cord. Also known as motor neuron diseases, they affect the motor functions of voluntary muscles in the body. Symptoms of ALS include muscle twitching and muscles decreasing in size. Factors such as an increase in the incidence rate of ALS, rise in the awareness about the disease among patients, and rise in the geriatric population is expected to boost the growth of the amyotrophic lateral sclerosis market.

The Global ALS market valuation is expected to surpass USD 841.6 million by 2023, growing at approximately 7.89 % CAGR over the forecast period (2018-2023). In 2017, the market had a valuation of USD 526 million.

Additional factors such as the inclination towards the sedentary lifestyle are driving the market growth and increasing the risk of developing ALS. Besides, the increasing geriatric population substantiates market growth, creating a demand for symptomatic and targeted treatment options.

But the high cost of the treatment of ALS may hinder the market growth over the forecast period.

Segmentation Analysis

The Global amyotrophic lateral sclerosis market has been segmented on the basis of type, treatment, and end-user.

By type, the market is segmented into sporadic and familial ALS. The sporadic ALS, also abbreviated as SALS, was the largest segment in 2017 and can dominate the market over the forecast period.

By treatment, the amyotrophic lateral sclerosis market has been segmented into medication, physical therapy, respiratory therapy, speech therapy, and others. Out of these, medication had the largest market in 2017.

By end-user, the ALS market has been segmented into hospitals, specialty centers, research & academic institutes, and others. Among these, the subsegment Hospital accounts for the largest segment.

Regional Analysis

By Regions, the global amyotrophic lateral sclerosis market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas is estimated to dominate the global ALS market owing to the increasing pool of awareness and the rising prevalence of hypertension. ALS remains a significant public health challenge in the US. Therefore, governments and private non-profit organizations are developing specific guidelines for the management and treatment of ALS. Public and private organizations are involved in strategic partnerships and collaborations in search for a better outcome in the research of amyotrophic lateral sclerosis treatment in the region.
The amyotrophic lateral sclerosis market in the European region stands at the second position in terms of the market size mainly due to the well-established healthcare sector. Several companies and research institutes are also establishing advanced facilities to research ALS.

Moreover, in recent years, there has been an increase in the adoption of sedentary lifestyles among people. Research shows that an increase in physical activities such as exercise helps in reducing the pain and thwarting some of the symptoms such as loss of motion in patients who have ALS.

Thus, the inclination towards the sedentary lifestyle increases the risk of developing ALS among the elderly population, thus creating a demand for symptomatic and targeted treatment options. The development of novel therapeutic approaches and advanced treatment options are likely to push the growth of the amyotrophic lateral sclerosis market during the forecast period.

Whereas, the ALS market in the Asia Pacific region is expected to grow rapidly due to the increasing prevalence of the disease and rapidly developing healthcare infrastructure. The increasing economy in the region is playing a vital role in the growth of the market. Furthermore, the increase in the setups of research and development centers also fuels the growth of the ALS market in the region.

Key Players

Market players profiled in the report are Sun Pharmaceutical (India), Mitsubishi Tanabe Pharma America (U.S.), Biogen (U.S.), Sanofi (France), Mylan N.V. (U.S.), Covis Pharma (Switzerland), Ionis Pharmaceutical (U.S.), ITF Pharma (U.S.), Ascend Pharmaceuticals LLC (U.S.), Apotex Inc. (Canada), and others.

Research Methodology

The research report - Global Amyotrophic Lateral Sclerosis Market comprises in-depth primary research and the detailed analysis of qualitative and quantitative aspects of various market experts. Key opinions of market leaders enable to gain a deeper insight into the performance of the market. The blow by blow detailed market analysis gives a clear picture of the current market scenarios including past and future market size in terms of value as well as volume alongside the technological advancement, macroeconomic factors, and governing factors of the market. The report provides detailed information and strategies of top-notch players in the market while providing a broad study of the market's various segments.

Analysis Period:

- Base Year - 2017
- Projection Period - 2018 to 2023
- Market Valuation - USD Million

For the scope of comprehension, the global amyotrophic lateral sclerosis market is segmented in the following manner.

Type:

- Sporadic ALS (SALS)
- Familial ALS (FALS)

Treatment:

- Medication
- Physical Therapy
- Respiratory Therapy
- Speech Therapy
End-user:

- Hospitals
- Specialty Centers
- Research & Academic Institutes
- Others

Region:

- Americas
  - The U.S.
  - Canada

- North America

- Latin America

- Europe
  - France
  - The U.K.
  - Germany
  - Italy
  - Spain
  - Rest of Western Europe
- Western Europe
- Eastern Europe

- Asia Pacific

- China

- Japan

- India

- Australia

- South Korea

- Rest of Asia Pacific

- Middle East & Africa
  - The Middle East
  - Africa
Infographic Summary:

GLOBALAMYOTROPHIC LATERAL SCLEROSIS MARKET

Global Amyotrophic Lateral Sclerosis Market, 2015 to 2023 (USD Million)

Market Size (USD Million)

<table>
<thead>
<tr>
<th>Year</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>841.6</td>
</tr>
</tbody>
</table>

Sporadic ALS: 55%
Familial ALS: 45%

39% Hospitals
Specialty Centers
Research and Academic Institutes
Others

MEDICATION
PHYSICAL THERAPY
RESPIRATORY THERAPY
SPEECH THERAPY
OTHERS
TABLE OF CONTENTS

1 Executive Summary
2 Market Introduction
   2.1 Definition 17
   2.2 Scope of the Study 17
   2.3 List of Assumptions 17
   2.4 Market Structure 18
3 Research Methodology
   3.1 Research Process 20
   3.2 Primary Research 21
   3.3 Secondary Research 22
   3.4 Market Size Estimation 23
   3.5 Forecast Model 23
4 Market Dynamics
   4.1 Overview 25
   4.2 Drivers 26
      4.2.1 Growing Incidence of Amyotrophic Lateral Sclerosis (ALS) 26
      4.2.2 Rising Geriatric Population 26
      4.2.3 Growing Awareness about Amyotrophic Lateral Sclerosis 26
   4.3 Restraints 27
      4.3.1 High Cost of ALS Treatment 27
   4.4 Opportunities 27
      4.4.1 Increasing Strategic Collaborations of Major Companies and Research Institutes for the Development of ALS Treatment 27
5 Market Factor Analysis
   5.1 Porter’s Five Forces Model 29
      5.1.1 Bargaining Power of Suppliers 30
      5.1.2 Bargaining Power of Buyers 30
      5.1.3 Threat of New Entrants 30
      5.1.4 Threat of Substitutes 30
      5.1.5 Intense Rivalry 30
   5.2 Value Chain Analysis 31
      5.2.1 Raw Material Sourcing 31
      5.2.2 Manufacturing 31
      5.2.3 Distribution & Sales 31
      5.2.4 Post-Sales Monitoring 32
   5.3 Investment Feasibility Analysis 32
   5.4 Pricing Analysis 32
6 Global Amyotrophic Lateral Sclerosis Market, by Type
   6.1 Overview 34
   6.2 Sporadic ALS 34
   6.3 Familial ALS 35
7 Global Amyotrophic Lateral Sclerosis Market, by Treatment
   7.1 Overview 37
   7.2 Medication 38
   7.3 Physical Therapy 39
   7.4 Respiratory Therapy 39
   7.5 Speech Therapy 40
   7.6 Others 40
8 Global Amyotrophic Lateral Sclerosis Market, by End User
   8.1 Overview 42
   8.2 Hospitals 42
   8.3 Specialty Centers 43
   8.4 Research and Academic Institutes 44
   8.5 Others 44
9 Global Amyotrophic Lateral Sclerosis Market, by Region
   9.1 Overview 46
   9.2 Americas 47
      9.2.1 North America 49
         9.2.1.1 US 51
      9.2.2 Canada 53
      9.2.2 Latin America 54
      9.3 Europe 56
         9.3.1 Western Europe 58
         9.3.1.1 Germany 61
         9.3.1.2 France 62
      9.3.1.3 UK 64
9.3.1.4 Italy 65
9.3.1.5 Spain 67
9.3.1.6 Rest of Western Europe 68
9.3.2 Eastern Europe 70
9.4 Asia-Pacific 72
9.4.1 Japan 74
9.4.2 Australia 76
9.4.3 China 77
9.4.4 India 79
9.4.5 South Korea 80
9.4.6 Rest of Asia-Pacific 82
9.5 Middle East & Africa 84
9.5.1 Middle East 86
9.5.2 Africa 88

10 Company Landscape
10.1 Overview 91
10.2 Company Ranking 91

11 Company Profile
11.1 Ascend Laboratories LLC 94
11.1.1 Company Overview 94
11.1.2 Financial Overview 94
11.1.3 Products/Services Offered 94
11.1.4 SWOT Analysis 95
11.1.5 Key Developments 95
11.1.6 Key Strategy 95
11.2 Apotex Inc. 96
11.2.1 Company Overview 96
11.2.2 Financial Overview 96
11.2.3 Products/Services Offered 96
11.2.4 SWOT Analysis 96
11.2.5 Key Developments 96
11.2.6 Key Strategy 96
11.3 Biogen 97
11.3.1 Company Overview 97
11.3.2 Financial Overview 97
11.3.3 Products/Services Offered 98
11.3.4 SWOT Analysis 98
11.3.5 Key Developments 98
11.3.6 Key Strategy 98
11.4 Covis Pharma 99
11.4.1 Company Overview 99
11.4.2 Financial Overview 99
11.4.3 Products/Services Offered 99
11.4.4 SWOT Analysis 100
11.4.5 Key Developments 100
11.4.6 Key Strategy 100
11.5 Ionis Pharmaceuticals 101
11.5.1 Company Overview 101
11.5.2 Financial Overview 101
11.5.3 Products/Services Offered 101
11.5.4 SWOT Analysis 102
11.5.5 Key Developments 102
11.5.6 Key Strategy 102
11.6 ITF Pharma 103
11.6.1 Company Overview 103
11.6.2 Financial Overview 103
11.6.3 Products/Services Offered 103
11.6.4 Key Developments 103
11.6.5 SWOT Analysis 103
11.6.6 Key Strategy 103
11.7 Mitsubishi Tanabe Pharma America 104
11.7.1 Company Overview 104
11.7.2 Financial Overview 104
11.7.3 Products/Services Offered 105
11.7.4 SWOT Analysis 105
11.7.5 Key Developments 105
11.7.6 Key Strategy 105
11.8 Mylan N.V. 106
11.8.1 Company Overview 106
11.8.2 Financial Overview 106
11.8.3 Products/Services Offered 107
11.8.4 SWOT Analysis 107
11.8.5 Key Developments 107
11.8.6 Key Strategy 107
11.9 Sanofi 108
11.9.1 Company Overview 108
11.9.2 Financial Overview 108
11.9.3 Products/Services Offered 108
11.9.4 SWOT Analysis 109
11.9.5 Key Developments 109